While DGKα inhibitors are highly unlikely to block these individual targets and pathways as effectively or potently as specific inhibitors for each, the combined inhibition of multiple targets—even to a lesser degree—may be a promising approach for a genetically heterogenous cancer such as GBM with diverse signaling drivers. The gene discussed is DGKA; the disease is cancer.